Liver health may change how this cancer drug works

NCT ID NCT07282093

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the body handles a single dose of the cancer drug olverembatinib in people with normal vs. impaired liver function. Researchers will measure drug levels and safety in 48 adults. The goal is to understand if liver problems require dose adjustments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATIC IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • The First Affiliated Hospital of Suzhou Medical University

    RECRUITING

    Suzhou, Jiangsu, 215006, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.